L-carnitine Oral Liquid On The Treatment Of Type 2 Diabetic Nephropathy Function And Metabolism Research

Aim To observe the efficacy of L-carnitine oral liquid in treatment of type 2 diabetic nephropathy and investigate the relationship between the time dependent change of carnitine pool level in body plasma and therapeutic effect.Methods To detect the concentration of carnitine pool including L-carnitine (LC), acetyl-L-carnitine (ALC) and propionyl-L-carnitine (PLC) in plasma of type 2 diabetic nephropathy patients by high performance liquid chromatography (HPLC). To select 40 cases of type 2 diabetic nephropathy patients belonging to early diabetic nephropathy (â…¢of DN) or clinical diabetic nephropathy group (the early group in IV of DN), which were randomly divided into control group and treatment group both containing 20 cases. Both groups should be given diabetes conventional treatment and should stop taking other lipid-lowering drugs, and the treatment group were additionally administrated L-carnitine oral liquid (1 g, bid) for 4 weeks. We observed the level changes of blood glucose (GLU), blood lipids (including TG, CHO, LDL-C, HDL-C), renal function (including BUN, Cr, UA)and urine protein(PRO) of the two groups of patients before and after LC treatment and detected the level time dependent changes and metabolism of carnitine pool in plasma. All the data before and after treatment was analysed by SPSS 17.0 statistical software.Results (1) For the control group before treatment compared with after treatment, and compared with the treatment group before treatment, there were no significant defference in blood glucose, blood lipids, renal function, urinary protein excretion, body weight, concentration of carnitine pool in plasma (P>0.05);(2) For the treatment group after treatment with LC for 2 and 4 weeks, the content of GLU, TG, CHO, LDL-C and weight was decreased significantly compared with before administration (P<0.01), while HDL-C was increased markedly (P<0.05); For the treatment group after treatment with LC for 4 weeks, the content of GLU was decreased significantly while HDL-C was increased significantly compared with the control group (P<0.01), and LDL-C was decreased markedly (P<0.05).(3) In the treatment group, after administration of LC for 4 weeks the content of BUN was decreased significantly compared with before administration (P<0.05); Treatment with LC for 2 and 4 weeks significantly reduced the level of urine protein excretion compared with before administration and control group (P<0.01);(4) Compared with the control group and before administration, LC, ALC and PLC levels in plasma after administration for 2 and 4 weeks were increased significantly (P<0.01). Compared with treatment with LC for 2 weeks, the concentration of LC in plasma was increased significantly after administration of LC for 4 weeks (P<0.01).Conclusions L-carnitine oral liquid has positive therapeutic effect on type 2 diabetic nephropathy, because it could increase the concentration of LC, ALC and PLC in plasma and regulate blood GLU, TG, CHO, LDL-C, HDL-C, BUN, weight and urinary protein significantly.